| Ytd | 67.20% | |
| 1y | 117.05% |
| Open | 13.29 | Prev Close | 13.14 | Low | 13.29 | High | 14.64 | Mkt Cap | 29.95M |
| Vol | 32.62K | Avg Vol | 53.22K | EPS | -4.90 | P/E | N/A | Forward P/E | N/A |
| Beta | -1.50 | Short Ratio | 0.08 | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 12.36 | 200-d Avg | 12.27 | 1yr Est | 0.00 |
PLRZ News
Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 69.4% to $1.12 during Monday's regul
Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage bio
Polyrizon completes contracting with all five U.S. clinical sites and advances its NASARIX™ study to
Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session.
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement
Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “
Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage bio
Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “
Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “
New performance and characterization study in collaboration with leading European medical center mar
New performance and characterization study in collaboration with leading European medical center mar
The application was published under European publication number EP 4751737. The patent application c
Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “
The study, titled "Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker
Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “
As previously announced, on February 4, 2026, Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company") a
The clinical site, located in Texas, will serve as the first participating center in Polyrizon's
Raanana, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “P
In light of the growing challenges posed by emerging respiratory threats, including recent Hantaviru
The amended claims expand the scope of protection of the Company's technology to include not onl
Raanana, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “P
This application focuses exclusively on protecting the Company's advanced intranasal drug delive
Raanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or
RAANANA, ISRAEL, April 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a
The transactions consisted of the sale of 388,888 Units (or Pre-Funded Units), each consisting of on
Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline A
Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or th
Under the terms of the MOU, two shareholders will sell to Polyrizon approximately 20% of the outstan
The Company signed a non-binding MOU with shareholders of Colugo. Colugo's customer include the Isra
Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage b
Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or th
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage bi
Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or th
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage bi
Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the
HONG KONG, Feb. 17, 2026 /PRNewswire/ -- Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinica
The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company
Collaboration aims to enhance bioavailability and support clinical advancement of Clearmind's le
The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage bi
Company Remains Fully Committed to Advancing Its Core Intranasal Medical Pipeline, alongside examini
As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.